版本:
中国

BRIEF-Acorda Therapeutics says expects results from Tozadenant phase 3 clinical trial in Q1 2018​

June 6 Acorda Therapeutics Inc

* Acorda Therapeutics Inc - expects results from an ongoing tozadenant phase 3 clinical trial in q1 2018​

* Acorda Therapeutics Inc - ‍ company initiated an open-label, long-term safety study for Tozadenant in Q2 of 2017​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐